Vincerx Pharma, Inc. VINC
We take great care to ensure that the data presented and summarized in this overview for Vincerx Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VINC
View all-
Prosight Management, LP Dallas, TX2.49MShares$1.74 Million0.63% of portfolio
-
Armistice Capital, LLC New York, NY1.99MShares$1.39 Million0.02% of portfolio
-
Sage Rhino Capital LLC1.7MShares$1.19 Million0.34% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD892KShares$624,2030.02% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct674KShares$471,9350.0% of portfolio
-
Goldman Sachs Group Inc New York, NY631KShares$441,9940.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA627KShares$439,2090.0% of portfolio
-
Exodus Point Capital Management, LP New York, NY478KShares$334,5670.0% of portfolio
-
Marshall Wace, LLP London, X0329KShares$229,9730.0% of portfolio
-
Geode Capital Management, LLC Boston, MA231KShares$161,5490.0% of portfolio
Latest Institutional Activity in VINC
Top Purchases
Top Sells
About VINC
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Insider Transactions at VINC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 11
2023
|
Alexander A. Seelenberger Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,500
+25.75%
|
$0
$0.95 P/Share
|
|
Aug 10
2023
|
Raquel E. Izumi |
BUY
Open market or private purchase
|
Indirect |
3,440
+3.88%
|
$0
$0.93 P/Share
|
|
Aug 10
2023
|
Tom C Thomas |
BUY
Open market or private purchase
|
Direct |
5,000
+2.22%
|
$0
$0.95 P/Share
|
|
Aug 10
2023
|
Ahmed Md Hamdy Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
5,400
+5.32%
|
$0
$0.96 P/Share
|
|
Aug 09
2023
|
Raquel E. Izumi |
BUY
Open market or private purchase
|
Indirect |
13,036
+13.75%
|
$0
$0.9 P/Share
|
|
Aug 09
2023
|
Ahmed Md Hamdy Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
16,900
+15.71%
|
$0
$0.95 P/Share
|
|
Dec 14
2022
|
Tom C Thomas |
BUY
Open market or private purchase
|
Indirect |
7,000
+41.18%
|
$0
$0.83 P/Share
|
|
Dec 14
2022
|
Ahmed Md Hamdy Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
35,280
+32.36%
|
$0
$0.87 P/Share
|
|
Dec 14
2022
|
Raquel E. Izumi |
BUY
Open market or private purchase
|
Indirect |
28,738
+29.48%
|
$0
$0.88 P/Share
|
|
Aug 25
2022
|
Christopher P. Lowe Director |
BUY
Open market or private purchase
|
Direct |
11,600
+22.48%
|
$11,600
$1.65 P/Share
|
|
Aug 24
2022
|
Christopher P. Lowe Director |
BUY
Open market or private purchase
|
Direct |
18,400
+39.32%
|
$18,400
$1.65 P/Share
|
|
Jun 27
2022
|
Raquel E. Izumi |
BUY
Open market or private purchase
|
Indirect |
40,000
+50.0%
|
$40,000
$1.41 P/Share
|
|
Jun 23
2022
|
Ahmed Md Hamdy Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
24,200
+38.61%
|
$24,200
$1.41 P/Share
|
|
Jun 09
2022
|
Laura I. Bushnell |
BUY
Open market or private purchase
|
Direct |
15,000
+43.86%
|
$15,000
$1.91 P/Share
|
|
Dec 23
2021
|
Sooin Hwang Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+0.76%
|
$30,000
$10.0 P/Share
|
|
Dec 22
2021
|
Ahmed Md Hamdy Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
6,450
+31.11%
|
$64,500
$10.02 P/Share
|
|
Dec 22
2021
|
Alexander A. Seelenberger Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,417
+16.21%
|
$24,170
$10.34 P/Share
|
|
Dec 22
2021
|
Laura I. Bushnell |
BUY
Open market or private purchase
|
Direct |
2,402
+36.37%
|
$24,020
$10.48 P/Share
|
|
Dec 22
2021
|
Tom C Thomas |
BUY
Open market or private purchase
|
Indirect |
1,000
+25.0%
|
$10,000
$10.23 P/Share
|
|
Aug 04
2021
|
Raquel E. Izumi |
BUY
Open market or private purchase
|
Indirect |
1,000
+50.0%
|
$11,000
$11.96 P/Share
|